Research shows that the drug Imatinib, usually prescribed for Leukemia and gastric cancer, halves mortality and shortens the stay of Covid patients at the ICU by a week. Imatinib is especially effective in the 20 percent most ill Covid patients. However, further research is needed. Follow-up studies will be done by Amsterdam OLVG, the Erasmus Medical Center, the Dijklander Hospital and by the World Health Organisation in the Remapcap study.
Read more (in Dutch)
PULSE Sport, a start-up from the Demonstrator Lab, has reached a significant milestone by winning the prestigious 14th Dutch Sports Innovation Award. The company’s flagship product, a cutting-edge athlete management system, integrates advanced software and artificial intelligence to revolutionize athlete health and performance monitoring. About the Innovation PULSE Sport’s athlete management system provides a holistic […]
NewsVU-AMS is on a mission to revolutionize how we understand and manage stress-related health issues. Now an official VU spin-off, there are big plans for clinical applications. Founder of VU AMS Martin Gevonden explains: “We offer researchers autonomic biomarkers that are valid, reliable and easy to use, without getting under the skin.” After thriving in […]
NewsAmsterdam researchers have secured Biotech Booster funding for a total of six projects, that include a promising cancer treatment, a new diagnostic method for Alzheimer’s Disease, an implant helping blindness, lab innovation in biotechnology, and a nutritional intervention for mental health. The researchers will develop a solid business case for their innovations in the time […]
News